AR104598A1 - Métodos para tratar trastornos linfoproliferativos asociados al virus de epstein-barr por terapia con células t - Google Patents

Métodos para tratar trastornos linfoproliferativos asociados al virus de epstein-barr por terapia con células t

Info

Publication number
AR104598A1
AR104598A1 ARP160101364A ARP160101364A AR104598A1 AR 104598 A1 AR104598 A1 AR 104598A1 AR P160101364 A ARP160101364 A AR P160101364A AR P160101364 A ARP160101364 A AR P160101364A AR 104598 A1 AR104598 A1 AR 104598A1
Authority
AR
Argentina
Prior art keywords
cells
epstein
methods
barr virus
linfoproliferative
Prior art date
Application number
ARP160101364A
Other languages
English (en)
Spanish (es)
Original Assignee
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56027234&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR104598(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Memorial Sloan Kettering Cancer Center filed Critical Memorial Sloan Kettering Cancer Center
Publication of AR104598A1 publication Critical patent/AR104598A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/50—Cellular immunotherapy characterised by the use of allogeneic cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ARP160101364A 2015-05-12 2016-05-11 Métodos para tratar trastornos linfoproliferativos asociados al virus de epstein-barr por terapia con células t AR104598A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562160549P 2015-05-12 2015-05-12

Publications (1)

Publication Number Publication Date
AR104598A1 true AR104598A1 (es) 2017-08-02

Family

ID=56027234

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP160101364A AR104598A1 (es) 2015-05-12 2016-05-11 Métodos para tratar trastornos linfoproliferativos asociados al virus de epstein-barr por terapia con células t

Country Status (18)

Country Link
US (1) US10568908B2 (OSRAM)
EP (1) EP3294304B1 (OSRAM)
JP (2) JP7284556B2 (OSRAM)
KR (1) KR102666781B1 (OSRAM)
CN (1) CN107835690A (OSRAM)
AR (1) AR104598A1 (OSRAM)
AU (1) AU2016262484B2 (OSRAM)
BR (1) BR112017024431B1 (OSRAM)
CA (1) CA2984178C (OSRAM)
CL (1) CL2017002846A1 (OSRAM)
FR (1) FR23C1025I2 (OSRAM)
IL (1) IL255581B (OSRAM)
MX (1) MX386334B (OSRAM)
NZ (1) NZ736675A (OSRAM)
PH (1) PH12017501993A1 (OSRAM)
RU (1) RU2720245C2 (OSRAM)
WO (1) WO2016183153A1 (OSRAM)
ZA (1) ZA201707335B (OSRAM)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017203356A1 (en) 2016-05-25 2017-11-30 The Council Of The Queensland Institute Of Medical Research Methods of immunotherapy
JP7002769B2 (ja) * 2016-09-16 2022-02-04 ベイラー カレッジ オブ メディスン ウイルス特異的ｔ細胞の活性化および拡大のためのプラットフォーム
AU2018355145A1 (en) 2017-10-23 2020-04-30 Atara Biotherapeutics, Inc. Methods of managing tumor flare in adoptive immunotherapy
CN108220237B (zh) * 2017-12-20 2020-11-06 中国科学院遗传与发育生物学研究所 一种人的nk/t细胞系
US20200350049A1 (en) * 2018-01-08 2020-11-05 Atara Biotherapeutics, Inc. Systems and methods for distributing cell therapies
EP3765602A1 (en) 2018-03-14 2021-01-20 Memorial Sloan Kettering Cancer Center Methods of selecting t cell line for adoptive cellular therapy
KR20220092905A (ko) * 2019-10-23 2022-07-04 더 카운실 오브 더 퀸즐랜드 인스티튜트 오브 메디컬 리서치 입양 면역요법
CN118256604B (zh) * 2024-04-16 2024-11-19 华中科技大学 一种利用人工抗原呈递细胞进行免疫原性肿瘤新抗原筛选与鉴定方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPO784197A0 (en) * 1997-07-10 1997-08-07 Csl Limited Treatment of nasopharyngeal carcinoma
US7163685B2 (en) * 2003-04-16 2007-01-16 City Of Hope Human cytomegalovirus antigens expressed in MVA and methods of use
JP4824389B2 (ja) * 2005-10-28 2011-11-30 株式会社医学生物学研究所 エプスタイン−バールウイルス感染細胞を特異的に攻撃する細胞傷害性ｔ細胞エピトープペプチド及びその用途
RU2506311C2 (ru) 2008-10-30 2014-02-10 Йеда Рисёрч Энд Девелопмент Ко. Лтд. Т-клетки центральной памяти против третьей стороны, способы их получения и их применение в трансплантации и лечении заболеваний
US20140086888A1 (en) 2010-09-01 2014-03-27 Helen E. Heslop Ebv-specific cytotoxic t-lymphocytes for the treatment of locoregional nasopharyngeal carcinoma (npc)
BR112014027957A8 (pt) * 2012-05-08 2018-01-16 Univ Johns Hopkins métodos e composições para infusão de populações selecionadas de enxerto transitório de linfócitos alogênicos para tratar câncer"
CA2889064A1 (en) * 2012-10-19 2014-04-24 The Council Of The Queensland Institute Of Medical Research Improved human herpesvirus immunotherapy
CN105848484A (zh) * 2013-10-25 2016-08-10 得克萨斯州大学系统董事会 用于免疫治疗的多克隆γδ T细胞
TWI673365B (zh) * 2014-11-05 2019-10-01 美國紀念斯隆 凱特琳癌症中心 選擇用於過繼性細胞療法之ｔ細胞株及其供體之方法
WO2017003763A1 (en) * 2015-06-27 2017-01-05 Memorial Sloan Kettering Cancer Center Methods of treating glioblastoma multiforme by t cell therapy

Also Published As

Publication number Publication date
CA2984178A1 (en) 2016-11-17
KR102666781B1 (ko) 2024-05-20
US10568908B2 (en) 2020-02-25
BR112017024431A2 (pt) 2018-07-24
RU2017143151A (ru) 2019-06-13
EP3294304A1 (en) 2018-03-21
AU2016262484B2 (en) 2021-10-21
MX386334B (es) 2025-03-18
CA2984178C (en) 2023-10-31
RU2017143151A3 (OSRAM) 2019-10-29
JP7284556B2 (ja) 2023-05-31
CN107835690A (zh) 2018-03-23
FR23C1025I2 (fr) 2025-04-18
AU2016262484A1 (en) 2018-01-04
IL255581B (en) 2021-03-25
ZA201707335B (en) 2021-02-24
RU2720245C2 (ru) 2020-04-28
PH12017501993A1 (en) 2018-03-26
HK1244697A1 (en) 2018-08-17
CL2017002846A1 (es) 2018-05-25
FR23C1025I1 (fr) 2023-07-21
KR20180003575A (ko) 2018-01-09
US20180125891A1 (en) 2018-05-10
NZ736675A (en) 2023-03-31
JP2018520095A (ja) 2018-07-26
MX2017014257A (es) 2018-04-20
EP3294304B1 (en) 2020-01-29
BR112017024431B1 (pt) 2021-10-13
WO2016183153A1 (en) 2016-11-17
IL255581A (en) 2018-01-31
JP2021119154A (ja) 2021-08-12

Similar Documents

Publication Publication Date Title
CL2017002846A1 (es) Métodos de tratamiento de trastornos linfoproliferativos asociados al virus de epstein-barr por terapia con células t.
CL2017003006A1 (es) Métodos de acondicionamiento de pacientes para tratamiento con linfocitos t
CL2018001522A1 (es) Focalización de péptidos para dirigir virus adenoasociados (aavs)
CL2017003005A1 (es) Métodos de diagnóstico para tratamiento con linfocitos t
CL2017002904A1 (es) Métodos y kits para tratar la depresión
CO2017004932A2 (es) Métodos para seleccionar una línea de células t y donador de la misma para terapia celular adoptiva
MX2013002207A (es) Vacunas contra el cancer cerebral basadas en peptido alfa 2 del receptor de interleucina 13.
MX2017004983A (es) Metodos para usar interleucina 10 para tratar enfermedades y trastornos.
NI201500150A (es) TRATAMIENTO DE CÁNCER CON DIHIDROPIRAZINO-PIRAZINAS×Se proporcionan en la presente método
ZA202503387B (en) Semaglutide in medical therapy
MX2018005825A (es) Celulas inmunes modificadas y usos de las mismas.
MX2014011855A (es) Sistemas y metodos para tratar una respuesta farmacodinamica adversa inducida por opioides.
CY1125113T1 (el) Συνθεσεις και μεθοδοι για χρηση στην αγωγη της ομοκυστινουριας
PH12015502266A1 (en) Methods and compositions using 4-amino-2-(2,6-dioxo-piperidine-3-yl)-isoindoline-1,3-dione for treatment and management of central nervous system cancers
BR112018067967A2 (pt) tratamento de pacientes com hipercolesterolemia familiar homozigótica por meio de terapia hipolipemiante
MX2018002816A (es) Metodos de tratamiento de mieloma multiple y leucemia de celulas plasmaticas mediante terapia de celulas t.
CO2017013361A2 (es) Angiogénesis usando células madre placentarias estimuladas
MX2021013351A (es) Terapias de combinacion.
MX2019003314A (es) Metodos de tratamiento de la elevacion de dominio 3 de inmunoglobulina de celula t y mucina (tim-3).
AR105142A1 (es) Métodos de tratamiento del glioblastoma multiforme con terapia de células t
DOP2014000258A (es) Tratamiento de la metástasis en el cerebro con una combinación de veliparib y una terapia con radiación en la totalidad del cerebro
AR105141A1 (es) Métodos de tratamiento de la retinitis por cmv por medio de terapia con células t
AR105701A1 (es) Métodos y estuches para tratar la depresión
MX2017005418A (es) Tratamiento de cancer y lesion de piel.
AR100237A1 (es) Laquinimod para el tratamiento de pacientes con esclerosis múltiple remitente recurrente (rrms) con un alto grado de discapacidad

Legal Events

Date Code Title Description
FB Suspension of granting procedure